← Leaderboards
Xiaolin Zi
University Of California-Irvine
$5,893,861
Attributed
$6,851,617
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $692.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,851,617 · 8
VA$0 · 2
By mechanism
R01$4,908,217 · 3
R21$1,276,150 · 4
UG3$667,250 · 1
I01$0 · 2
Top collaborators
- Anshu Agrawal4 shared
- Michael B Lilly3 shared
Most similar at University Of California-Irvine
Same institution · by research overlap
- Mahtab Jafari$391,160
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCancer PatientCellsIn VivoMalignant NeoplasmsOverexpressionImmunohistochemistryBaseMediatingMalignant Neoplasm Of ProstateGrowthMouse ModelPathway InteractionsChemopreventive AgentPlayPreventReportingToxic EffectDiagnosisIncidenceAffectNormal CellIn VitroCarcinogenesis
Grant awards (34)
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer$359,138
R01 · FY2025 · CA · contact PI
Nautral products for targeting Skp2 in cancer interception$333,625
UG3 · FY2025 · CA · contact PI
A novel targetable mechanism for castration-resistant prostate cancer$0
I01 · FY2025 · VA · contact PI
CMA-Basic and Translational Mechanisms of Cancer Initiation of the Urothelium in Veterans Exposed to Carcinogens: Interception of tobacco smoking-related bladder cancer by an epigenetic approach$0
I01 · FY2025 · VA · contact PI
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer$341,181
R01 · FY2024 · CA · contact PI
Nautral products for targeting Skp2 in cancer interception$333,625
UG3 · FY2024 · CA · contact PI
CMA-Basic and Translational Mechanisms of Cancer Initiation of the Urothelium in Veterans Exposed to Carcinogens: Interception of tobacco smoking-related bladder cancer by an epigenetic approach$0
I01 · FY2024 · VA · contact PI
A novel targetable mechanism for castration-resistant prostate cancer$0
I01 · FY2024 · VA · contact PI
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer$351,711
R01 · FY2023 · CA · contact PI
CMA-Basic and Translational Mechanisms of Cancer Initiation of the Urothelium in Veterans Exposed to Carcinogens: Interception of tobacco smoking-related bladder cancer by an epigenetic approach$0
I01 · FY2023 · VA · contact PI
A novel targetable mechanism for castration-resistant prostate cancer$0
I01 · FY2023 · VA · contact PI
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer$370,628
R01 · FY2022 · CA · contact PI
CMA-Basic and Translational Mechanisms of Cancer Initiation of the Urothelium in Veterans Exposed to Carcinogens: Interception of tobacco smoking-related bladder cancer by an epigenetic approach$0
I01 · FY2022 · VA · contact PI
A novel targetable mechanism for castration-resistant prostate cancer$0
I01 · FY2022 · VA · contact PI
The NEDD8 pathway mediated Skp2 degradation in chemoprevention by FKA$353,419
R01 · FY2020 · CA · contact PI
The NEDD8 pathway mediated Skp2 degradation in chemoprevention by FKA$341,359
R01 · FY2019 · CA · contact PI
The NEDD8 pathway mediated Skp2 degradation in chemoprevention by FKA$364,385
R01 · FY2018 · CA · contact PI
The NEDD8 pathway mediated Skp2 degradation in chemoprevention by FKA$353,419
R01 · FY2017 · CA · contact PI
The NEDD8 pathway mediated Skp2 degradation in chemoprevention by FKA$353,419
R01 · FY2016 · CA · contact PI
Phase 1 Bioassay-guided Trial of Lycopene and Docetaxel for Prostate Cancer$159,412
R21 · FY2014 · CA
Phase 1 Bioassay-guided Trial of Lycopene and Docetaxel for Prostate Cancer$209,900
R21 · FY2013 · CA
Chemoprevention of urinary bladder carcinogenesis by flavokawain A$310,248
R01 · FY2012 · CA · contact PI
Rhodiola Rosea Extracts, Salidroside and Bladder Cancer Chemoprevention$166,388
R21 · FY2012 · CA · contact PI
Chemoprevention of urinary bladder carcinogenesis by flavokawain A$310,248
R01 · FY2011 · CA · contact PI
Rhodiola Rosea Extracts, Salidroside and Bladder Cancer Chemoprevention$199,665
R21 · FY2011 · CA · contact PI
Chemoprevention of urinary bladder carcinogenesis by flavokawain A$86,059
R01 · FY2011 · CA · contact PI
Chemoprevention of urinary bladder carcinogenesis by flavokawain A$319,843
R01 · FY2010 · CA · contact PI
Chemoprevention of urinary bladder carcinogenesis by flavokawain A$39,922
R01 · FY2010 · CA · contact PI
Chemoprevention of urinary bladder carcinogenesis by flavokawain A$319,335
R01 · FY2009 · CA · contact PI
Chemoprevention of urinary bladder carcinogenesis by flavokawain A$333,903
R01 · FY2008 · CA · contact PI
Lycopene & Docetaxel in Prostate Cancer: An IGF-I Receptor Targeting Approach$152,584
R21 · FY2008 · CA · contact PI
Lycopene & Docetaxel in Prostate Cancer: An IGF-I Receptor Targeting Approach$183,000
R21 · FY2007 · CA · contact PI
Kava extract, Flavokawains and Bladder Cancer Prevention$102,938
R21 · FY2005 · CA
Kava extract, Flavokawains and Bladder Cancer Prevention$102,263
R21 · FY2004 · CA